A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Small Cell Lung Cancer
Ovarian Cancer
Gastric Cancer
Hormone-receptor-positive Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer
Advanced Solid Tumor
Endometrial Cancer
Prostate Cancer
TNBC - Triple-Negative Breast Cancer
GastroEsophageal Cancer
Bladder Cancer

Interventions

DRUG: BG-68501
DRUG: Fulvestrant
DRUG: BGB-43395

Sponsor

BeiGene